Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.

Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.

PMID:
30424892
2.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators.

N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389. [Epub ahead of print]

PMID:
30415602
3.

A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.

Shestakova MV, Wilding JPH, Wilpshaar W, Tretter R, Orlova VL, Verbovoy AF.

Diabetes Res Clin Pract. 2018 Dec;146:240-250. doi: 10.1016/j.diabres.2018.10.018. Epub 2018 Nov 1.

4.

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH.

Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16.

PMID:
30122305
5.

Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography.

Psarou A, Cooper H, Wilding JPH.

Diabetes Ther. 2018 Oct;9(5):1791-1810. doi: 10.1007/s13300-018-0490-5. Epub 2018 Aug 17. Review.

6.

Vitamin D receptor ligands attenuate the inflammatory profile of IL-1β-stimulated human white preadipocytes via modulating the NF-κB and unfolded protein response pathways.

Zhu J, Bing C, Wilding JPH.

Biochem Biophys Res Commun. 2018 Sep 5;503(2):1049-1056. doi: 10.1016/j.bbrc.2018.06.115. Epub 2018 Jun 23.

PMID:
29935184
7.

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS.

Am Heart J. 2018 Jun;200:83-89. doi: 10.1016/j.ahj.2018.01.012. Epub 2018 Feb 7.

PMID:
29898853
8.

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M; CVD-REAL Investigators and Study Group.

J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506. doi: 10.1016/j.jacc.2018.01.085.

9.

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

Thuresson M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Wittbrodt E, Hammar N, Fenici P, Kosiborod M; CVD-REAL Investigators and Study Group.

Diabetes Care. 2018 Jun;41(6):e106-e108. doi: 10.2337/dc18-0338. No abstract available.

PMID:
29784708
10.

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.

Ahrén B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, Holst AG, Leiter LA.

Diabetes Obes Metab. 2018 Sep;20(9):2210-2219. doi: 10.1111/dom.13353. Epub 2018 Jun 12.

11.

Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.

Wilding JPH.

Clin Obes. 2018 Jun;8(3):211-225. doi: 10.1111/cob.12248. Epub 2018 Apr 24.

12.

Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes.

Bowden Davies KA, Sprung VS, Norman JA, Thompson A, Mitchell KL, Halford JCG, Harrold JA, Wilding JPH, Kemp GJ, Cuthbertson DJ.

Diabetologia. 2018 Jun;61(6):1282-1294. doi: 10.1007/s00125-018-4603-5. Epub 2018 Apr 18.

PMID:
29671031
13.

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.

Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

Diabetes Obes Metab. 2018 Aug;20(8):1983-1987. doi: 10.1111/dom.13299. Epub 2018 Apr 17.

14.

Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group.

Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847. No abstract available.

PMID:
29483180
15.

Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome.

Shillito JA, Lea J, Tierney S, Cleator J, Tai S, Wilding JPH.

Appetite. 2018 Jun 1;125:270-277. doi: 10.1016/j.appet.2018.02.005. Epub 2018 Feb 14.

PMID:
29454015
16.

Newer GLP-1 receptor agonists and obesity-diabetes.

Brown E, Cuthbertson DJ, Wilding JP.

Peptides. 2018 Feb;100:61-67. doi: 10.1016/j.peptides.2017.12.009. Review.

PMID:
29412833
17.

DECLARE-TIMI 58: Participants' baseline characteristics.

Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD.

Diabetes Obes Metab. 2018 May;20(5):1102-1110. doi: 10.1111/dom.13217. Epub 2018 Feb 14.

PMID:
29322605
18.

Combination therapy for obesity.

Wilding JP.

J Psychopharmacol. 2017 Nov;31(11):1503-1508. doi: 10.1177/0269881117737401. Epub 2017 Nov 13. Review.

PMID:
29132230
19.

Evaluation of Aintree LOSS, a community-based, multidisciplinary weight management service: outcomes and predictors of engagement.

Steele T, Narayanan RP, James M, James J, Mazey N, Wilding JPH.

Clin Obes. 2017 Dec;7(6):368-376. doi: 10.1111/cob.12216. Epub 2017 Sep 4.

PMID:
28871633
20.

Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction.

Ashrafi R, Modi P, Oo AY, Pullan DM, Jian K, Zhang H, Gerges JY, Hart G, Boyett MR, Davis GK, Wilding JPH.

Exp Physiol. 2017 Nov 1;102(11):1424-1434. doi: 10.1113/EP086412. Epub 2017 Sep 24.

PMID:
28804970
21.

Screening methods for obstructive sleep apnoea in severely obese pregnant women.

Longworth H, McCallin K, Narayanan RP, Turner MA, Quenby S, Rycroft D, Charnley M, Abayomi J, Topping J, Weeks AD, Wilding JPH.

Clin Obes. 2017 Aug;7(4):239-244. doi: 10.1111/cob.12196. Epub 2017 May 29.

PMID:
28557355
22.

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*.

Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18.

23.

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.

Budoff MJ, Wilding JPH.

Int J Clin Pract. 2017 May;71(5). doi: 10.1111/ijcp.12948. Review.

24.

Medication use for the treatment of diabetes in obese individuals.

Wilding JPH.

Diabetologia. 2018 Feb;61(2):265-272. doi: 10.1007/s00125-017-4288-1. Epub 2017 May 14. Review.

PMID:
28501906
25.

Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation.

Bray GA, Kim KK, Wilding JPH; World Obesity Federation.

Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. Review.

PMID:
28489290
26.

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.

O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups.

Diabetes Obes Metab. 2017 Nov;19(11):1529-1536. doi: 10.1111/dom.12963. Epub 2017 Jul 21.

27.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group.

Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Erratum in: Lancet. 2017 Apr 8;389(10077):1398.

PMID:
28237263
28.

Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.

Rajeev SP, Sprung VS, Roberts C, Harrold JA, Halford JC, Stancak A, Boyland EJ, Kemp GJ, Cuthbertson DJ, Wilding JP.

BMJ Open. 2017 Jan 27;7(1):e013539. doi: 10.1136/bmjopen-2016-013539.

29.

What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications?

Cuthbertson DJ, Steele T, Wilding JP, Halford JC, Harrold JA, Hamer M, Karpe F.

Int J Obes (Lond). 2017 Jun;41(6):853-865. doi: 10.1038/ijo.2017.4. Epub 2017 Jan 12. Review.

PMID:
28077863
30.

Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response.

Thondam SK, Daousi C, Wilding JP, Holst JJ, Ameen GI, Yang C, Whitmore C, Mora S, Cuthbertson DJ.

Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E224-E233. doi: 10.1152/ajpendo.00347.2016. Epub 2017 Jan 10.

31.

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE.

Diabetes. 2017 Feb;66(2):241-255. doi: 10.2337/db16-0806. Epub 2016 Dec 15. Review.

32.

Research update for articles published in EJCI in 2014.

Agra RM, Al-Daghri NM, Badimon L, Bodi V, Carbone F, Chen M, Cubedo J, Dullaart RP, Eiras S, García-Monzón C, Gary T, Gnoni A, González-Rodríguez Á, Gremmel T, Hafner F, Hakala T, Huang B, Ickmans K, Irace C, Kholová I, Kimer N, Kytö V, März W, Miazgowski T, Møller S, Montecucco F, Niccoli G, Nijs J, Ozben S, Ozben T, Papassotiriou I, Papastamataki M, Reina-Couto M, Rios-Navarro C, Ritsch A, Sabico S, Seetho IW, Severino A, Sipilä J, Sousa T, Taszarek A, Taurino F, Tietge UJ, Tripolino C, Verloop W, Voskuil M, Wilding JP.

Eur J Clin Invest. 2016 Oct;46(10):880-94. doi: 10.1111/eci.12671. No abstract available.

PMID:
27571922
33.

Weighing up dietary patterns - Authors' reply.

Bray GA, Frühbeck G, Ryan DH, Wilding JP.

Lancet. 2016 Aug 20;388(10046):759-60. doi: 10.1016/S0140-6736(16)31359-9. No abstract available.

PMID:
27560275
34.

Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm.

Wilding JP, Rajeev SP, DeFronzo RA.

Diabetes Care. 2016 Aug;39 Suppl 2:S154-64. doi: 10.2337/dcS15-3005. Review.

PMID:
27440828
35.

Management of obesity.

Bray GA, Frühbeck G, Ryan DH, Wilding JP.

Lancet. 2016 May 7;387(10031):1947-56. doi: 10.1016/S0140-6736(16)00271-3. Epub 2016 Feb 10. Review.

PMID:
26868660
36.

Exposure-response analyses of liraglutide 3.0 mg for weight management.

Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW.

Diabetes Obes Metab. 2016 May;18(5):491-9. doi: 10.1111/dom.12639. Epub 2016 Mar 1.

37.

Fit for Birth - the effect of weight changes in obese pregnant women on maternal and neonatal outcomes: a pilot prospective cohort study.

Narayanan RP, Weeks AD, Quenby S, Rycroft D, Hart A, Longworth H, Charnley M, Abayomi J, Topping J, Turner MA, Wilding JP.

Clin Obes. 2016 Feb;6(1):79-88. doi: 10.1111/cob.12129. Epub 2016 Jan 6.

PMID:
26781604
38.
39.

Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment.

Seetho IW, Ramírez-Torres A, Albalat A, Mullen W, Mischak H, Parker RJ, Craig S, Duffy N, Hardy KJ, Burniston JG, Wilding JP.

Sleep Sci. 2015 Apr-Jun;8(2):58-67. doi: 10.1016/j.slsci.2015.06.004. Epub 2015 Jul 17.

40.

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.

Rajeev SP, Cuthbertson DJ, Wilding JP.

Diabetes Obes Metab. 2016 Feb;18(2):125-34. doi: 10.1111/dom.12578. Epub 2015 Dec 10. Review.

PMID:
26403227
41.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group.

N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.

42.

Serum urate and obstructive sleep apnoea in severe obesity.

Seetho IW, Parker RJ, Craig S, Duffy N, Hardy KJ, Wilding JP, Goodson NJ.

Chron Respir Dis. 2015 Aug;12(3):238-46. doi: 10.1177/1479972315586197. Epub 2015 May 19.

PMID:
25990129
43.

Cerebral activations during viewing of food stimuli in adult patients with acquired structural hypothalamic damage: a functional neuroimaging study.

Steele CA, Powell JL, Kemp GJ, Halford JC, Wilding JP, Harrold JA, Kumar SV, Cuthbertson DJ, Cross AA, Javadpour M, MacFarlane IA, Stancak AA, Daousi C.

Int J Obes (Lond). 2015 Sep;39(9):1376-82. doi: 10.1038/ijo.2015.82. Epub 2015 May 14.

PMID:
25971928
44.

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.

Cefalu WT, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G.

Diabetologia. 2015 Jun;58(6):1183-7. doi: 10.1007/s00125-015-3547-2. Epub 2015 Mar 27.

45.

Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus.

Wilding JP, Blonde L, Leiter LA, Cerdas S, Tong C, Yee J, Meininger G.

J Diabetes Complications. 2015 Apr;29(3):438-44. doi: 10.1016/j.jdiacomp.2014.12.016. Epub 2014 Dec 31.

46.

Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea.

Seetho IW, Asher R, Parker RJ, Craig S, Duffy N, Hardy KJ, Wilding JP.

Sleep Breath. 2015 Dec;19(4):1155-65. doi: 10.1007/s11325-015-1131-0. Epub 2015 Feb 6.

PMID:
25655633
47.

Impact of bariatric surgery on physical functioning in obese adults.

Steele T, Cuthbertson DJ, Wilding JP.

Obes Rev. 2015 Mar;16(3):248-58. doi: 10.1111/obr.12247. Epub 2015 Jan 12. Review.

PMID:
25580667
48.

Characteristics and perspectives of night-eating behaviour in a severely obese population.

Cleator J, Judd P, James M, Abbott J, Sutton CJ, Wilding JP.

Clin Obes. 2014 Feb;4(1):30-8. doi: 10.1111/cob.12037. Epub 2013 Nov 12.

PMID:
25425130
49.

A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.

Boyle LD, Wilding JP.

Expert Opin Drug Saf. 2014 Nov;13(11):1535-44. doi: 10.1517/14740338.2014.959488. Review.

PMID:
25340618
50.

Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome.

Seetho IW, Wilding JP.

Chron Respir Dis. 2014 Nov;11(4):257-75. doi: 10.1177/1479972314552806. Epub 2014 Oct 3. Review.

PMID:
25281562

Supplemental Content

Loading ...
Support Center